Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-02-03
2009-08-18
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S330000
Reexamination Certificate
active
07576061
ABSTRACT:
The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pmis the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, ptmay also be 1.
REFERENCES:
patent: 5312899 (1994-05-01), Schiller
patent: 5602100 (1997-02-01), Brown et al.
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5885958 (1999-03-01), Zadina et al.
patent: 5993848 (1999-11-01), Suzuki et al.
patent: 5994372 (1999-11-01), Yaksh
patent: 6221355 (2001-04-01), Dowdy
patent: 6268398 (2001-07-01), Ghosh et al.
patent: 6503713 (2003-01-01), Rana
patent: 6703483 (2004-03-01), Schiller
patent: 6759520 (2004-07-01), Carr et al.
patent: 6900178 (2005-05-01), Oeltgen et al.
patent: 2005/0096333 (2005-05-01), Dugar et al.
patent: 2005/0192215 (2005-09-01), Ghosh et al.
patent: 2007/0015711 (2007-01-01), Szeto
patent: 2007/0129306 (2007-06-01), Szeto et al.
patent: 2361364 (2000-09-01), None
patent: WO 9522557 (1995-08-01), None
patent: WO 00/55189 (2000-09-01), None
patent: WO 02/05748 (2002-01-01), None
File MEDLINE on STN An No. 2005478947. Simmons, Zachary. “Management Strageies for Patients with Amyotrphoic Lateral Sclerosis from diagnosis Through Death.” The Neurologist (Sep. 2005), vol. 11, No. 5, pp. 257-270. Abstract only.
Azzouz, Mimoun “Gene Therapy for ALS: Progress and Prospects” Biochemical et Biophysica Acta (2006), vol. 1762 pp. 112-1127.
Margolis et al. ‘Diagnosis of Huntington Disease’ Clinical Chemistry, vol. 49, No. 10 pp. 1726-1732 (2003).
Korczyn et al. ‘Emerging Therapies in the Pharmacological Treatment of Parkinson's Disease’ Drugs vol. 62, No. 5 pp. 775-786. 2002.
Sriram et al. ‘Experimental Allergic Encephalomyetlitis: A Misleading Model of Multiple Sclerosis’ Ann. Neurol. vol. 58, pp. 939-945. 2005.
Steinman et al. ‘How to Successfully Apply Animal Studies in Experimental Allergic Encephalomyelitis to Research on Multple Sclerosis’ Ann Neurol. vol. 60, pp. 12-21. 2006.
Citron, Martin, ‘Alzheimer's Disease: Treatment in Discovery and Development’ Nature Nuerosicence Supplment. vol. 5. pp. 1055-1057. Nov. 2002.
Patel et al. Pharmacotherapy of Cognitive Impariment in Alzheimer's Disease: A Review J. Geriatr. Psychiatry Neruol. vol. 8 pp. 81-95. 1995.
Herve et al. On the Immunogenic Properties of Retro-Inverso Peptides. Total Retro-Inversion of T- Cell Epitopes Causes a Loss of Binding to MHC ll Molecules Molecular Immunology. vol. 34, No. 2, pp. 157- 163.
Broekemeier, et al., “Inhibition of the Mitochondrial Permeability Transition by Cyclosporin A during Long Time Frame Experiments: Relationship between Pore Opening and the Activity of Mitochondrial Phospholipases”,Biochemistry1995, 34:16440-16449.
Wu, et al., “A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning”, Am J Physiol Heart Circ Physiol 2002, 283:H783-H791.
Clapp III, et al. “Cardiovascular and Metabolic Responses to Two Receptor-Selective Opioid Agonists in Pregnant Sheep”, Am. J. Obstet. Gynecol., vol. 178, No. 2 (Feb. 1998) pp. 397-401.
Holsey, et al. “Cardiovascular Effects of a μ-Selective Opioid Agonist (Tyrosine-D-Arginine-Phenylalanine-Lysine-NH2) in Fetal Sheep: Sites and Mechanisms of Action”, Am. J. Obstet. Gynecol., vol. 180, No. 5 (May 1999) pp. 1127-1130.
Kett, et al. “Baroreflex-Mediated Bradycardia but Not Tachycardia is Blunted Peripherally by Intravenous μ-opioid Agonists”, Am. J. Obstet. Gynecol., vol. 178, No. 5 (May 1998) pp. 950-955.
Neilan, et al. “Pharmacological Characterization of the Dermorphin Analog [Dmt1]DALDA, a Highly Potent and Selective μ-Opioid Peptide”, European Journal of Pharmacology, vol. 419, Issue 1 (2001) 15-23.
Omoniyi, et al. “A Peripheral Site of Action for the Attenuation of Baroreflex-Mediated Bradycardia by Intravenous μ-Opioid Agonists”, Journal of Cardiovascular Pharmacology ™, vol. 35, No. 2 (2000) pp. 269-274.
Schiller, et al. “Dermorphin Analogucs Carrying an Increased Positive Net Charge in Their “Message” Domain Display Extremely High μ Opioid Receptor Selectivity”, Journal of Medicinal Chemistry, vol. 32, No. 3 (1989) pp. 698-703.
Schiller, et al. “Synthesis and In Vitro Opioid Activity Profiles of DALDA Analogues”, European Journal of Medicinal Chemistry, vol. 35, Issue 10 (Oct. 2000) pp. 895-901.
Shimoyama, et al. “Antinociceptive and Respiratory Effects of Intrathecal H-Tyr-D-Arg-Phe-Lys-NH2(DALDA) and [Dmt1] DALDA”, The Journal of Pharmacology and Experimental Therapeutics, vol. 297, No. 1 (Apr. 2001) pp. 364-371.
Szeto, et al. “In Vivo Disposition of Dermorphin Analog (DALDA) in Nonpregnant and Pregnant Sheep”, The Journal of Pharmacology and Experimental Therapeutics, vol. 284, No. 1 (1998) pp. 61-65.
Szeto et al. “Respiratory Depression After Intravenous Administration of δ-Selective Opioid Peptide Analogs”, Peptides, vol. 20 (1999) pp. 101-105.
Szeto, et al. “Mu-Opioid Receptor Densensitization and Resensitization In Vivo”, International Narcotics Research Conference, Poster Abstracts, Monday (1999) Mon19, p. 5.
Szeto, et al. “In Vivo Pharmacokinetics of Selective μ-Opioid Peptide Agonists”, The Journal of Pharmacology and Experimental Therapeutics, vol. 298, No. 1 (Jul. 2001) pp. 57-61.
Wu, et al. “Myocardial Protective Effect of Mu Opioid Agonists”, International Narcotics Research Conference, Poster Abstracts, Sunday (1999) Sun59, p. 15.
Schiller, et al., “Opioid peptide analogs with novel activity profiles as potential therapeutic agents for use in analgesia”, Peptide Science-Present and Future, Proc. Int. Pept. Symp., 1st, Y. Shimonishi (ed), 1999, pp. 665-669.
Schiller, et al., “Opioid Peptide Analogs With Novel Activity Profiles as Potential Therapeutic Agents for Use in Analgesia”, First International Peptide Symposium, Program & Abstracts, Nov. 30-Dec. 5, 1997, Kyoto, Japan, 0-36, p. 77.
Zhao, et al., “Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondria Membrane inhibit Mitochondria Swelling, Oxidative Cell Death, and Reperfusion Injury”, J. Biol. Chem., Aug. 2004, vol. 279, No. 33, pp. 34682-34690.
Pages et al., “Cystamine and Cysteamine Increase Brain Levels of BDNF in Huntington Disease Via HSJ1b and Transglutaminase”, Journal of Clinical Investigation, vol. 116 No. 5, pp. 1410-1424. May 2006.
Berendsen, Herman, “A Glimpse of the Holy Grail?”, Science, vol. 282, pp. 642-643, Oct. 23, 1998.
Bradley et al., “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat”, J. Mol. Biol. vol. 324, pp. 373-386. 2002.
Rudinger, J. (1976), Peptide Hormones (Ed. J.A. Parson), University Park Press, Baltimore, pp. 1-7.
Ngo, et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problem and Tertiary Structure Prediction, K. Merz, Jr. And S. Le Grand, Editors, Birkhauser Boston, 1994.
James A Wells, “Additivity of Mutational Effects in Proteins”, Biochemistry, American Chemical Society, vol. 29, No. 37, Sep. 18, 1990.
Guerrini, et al., “Opioid receptor selectivity alteration by single residue replacement: synthesis
Schiller Peter W.
Szeto Hazel H.
Zhao Kesheng
Cornell Research Foundation Inc.
Foley & Lardner LLP
Gupta Anish
Institute de Recherches Clinques de Montreal
LandOfFree
Methods for preventing mitochondrial permeability transition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for preventing mitochondrial permeability transition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for preventing mitochondrial permeability transition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4068353